



(51) International Patent Classification:

G01N 33/50 (2006.01) A61K 31/7068 (2006.01)

G01N 33/543 (2006.01)

(21) International Application Number:

PCT/US2018/055961

(22) International Filing Date:

15 October 2018 (15.10.2018)

(25) Filing Language:

English

(26) Publication Language:


English

(30) Priority Data:

62/572,126 13 October 2017 (13.10.2017) US

(71) Applicant: **URSURE, INC. HARVARD LIFE LAB**
[US/US]; 700 Soldiers Field Road, 8 HBS Main Center,
Boston, MA 02163 (US).

(72) Inventors; and

(71) Applicants: **DAUGHTRIDGE, Giffin** [US/US]; 367 Har-
vard Street, Unit 2, Cambridge, MA 02138 (US). **KAR-**
DOS, Keith [US/US]; 1535 Highland Drive, Bethlehem,
PA 18015 (US).(74) Agent: **LENEY, Sardiaa, S.**; Wolf, Greenfield & Sacks,
P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).(54) Title: PRODUCTS AND METHODS FOR MONITORING ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE
INHIBITOR THERAPY**FIG. 1**

(57) Abstract: The invention provides novel compounds, reagents, systems, and methods for detecting a metabolite related to a NRTI in a biological sample, and use thereof in monitoring adherence to pre-exposure prophylaxis or anti-retroviral treatment. Such reagents comprise NRTI derivatives, analogs, NRTI derivatives conjugates, along with antibodies directed to same, which are useful for antibody-based methods, such as a lateral flow immunoassay and other point of care devices.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*